Business Wire

The District Hospital Santarém to Adopt Biolog Transfusion Solution to Improve Red Blood Cells Traceability

29.3.2021 14:57:00 EEST | Business Wire | Press release

Share

The District Hospital of Santarém, a well-recognized healthcare center located in the central region of Portugal, has chosen Biolog Transfusion Solution to optimize its blood components’ management between its healthcare services and blood transfusion department. In operation since November 2020, this solution provides real-time traceability to red blood cells, from reception to release for transfusion.

Based on RFID, Biolog Transfusion Solution connects healthcare professionals to essential product information. By offering real-time precise physical location for each blood product unit, this cutting-edge technology helps to better drive inventory management and enhance patients’ blood product reservations. Besides, this traceability allows unused red blood cell bags to be more reliably returned to the Blood Bank for potential new patient assignation before the expiration date. Combining the technology with 24/7 accurate digital information contributes to better utilization of available products and in reducing wastage, a key requirement when we know that about 5% of these vital resources can be unavailable for medical usage1.

“The implementation of the Biolog Transfusion Solution proved to be a good tool to improve the traceability of the transfusion process and, consequently, the quality of the service provided by the blood transfusion department. By tracking red blood bags, it’s possible to obtain information on all procedures performed with them, from reception at the department to transfusion at the inpatient service”, said Dra Rute Ribeiro, technical coordinator and responsible for quality of Santarém District Hospital Blood Bank.

“We have worked alongside the District Hospital of Santarém to define the right tools for facing their challenges, and we are pleased to see that Biolog Transfusion Solution meets their needs. At biolog-id we are committed to developing state of the art solutions to ensure the availability and the quality of blood products which will ultimately serve patients”, declares Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id.

“The real time capacity to locate blood components, as well as monitoring transfusion processes is the main achievement made possible by using RFID technology. That is really a forwarding security step!”, explains Dr. João Moura, Director of Santarém District Hospital Blood Bank.

By combining software, equipment, and tags, the modular end-to-end Biolog Transfusion Solution offers traceability of blood components products at every stage of the process. Biolog-id’s flexible approach allows customization of the solution to meet any infrastructure constraints, from blood centers, blood banks, and hospitals.

About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds.

Company URL: www.biolog-id.com

About District Hospital of Santarém:
The District Hospital of Santarém (HDS) is a Corporate Public Entity located in the city of Santarém in the central region of Portugal, in full operation since 1985. The Hospital is part of the Portuguese National Health Service (SNS).
The Hospital was projected in the late 70's with more than 500 beds and the objective of offering a new health infrastructure for the city. The Hospital is equipped with all the main medical and surgical specialties, serving a population of approximately 200,000 inhabitants. It has now a total of 419 beds, where more than 6,000 blood transfusions are delivered each year.

Website URL: https://www.hds.min-saude.pt/

About Xerys Gestion:
Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies. As such, Xerys Gestion supports companies in industries undergoing major transformation to address economic, environmental and societal challenges that have great ambitions for their growth and international expansion. In its market, Xerys Gestion stands out as much for its modus operandi and the strategic and operational support it provides to portfolio companies, as for the range of à la carte investment opportunities offered to investors and the firm’s close relations with them, or its sector-based approach. Lastly, Xerys Gestion has considerable sector expertise, bolstered by a strategic committee made up of recognized specialists and experts in key sectors. Xerys Gestion manages 200 million euros in assets, with a portfolio of nine companies.

For more information visit www.xerys.com or find us on LinkedIn @Xerys.

1 Source: World Health Organization

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contact: Astrid Billard, astrid.billard@biolog-id.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dubai Records the World’s Lowest Electricity Customer Minutes Lost at Just 49 Seconds Per Year29.4.2026 15:47:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA), announced that DEWA has set a new world record for the lowest electricity customer minutes lost (CML), at just 0.82 minutes (about 49 seconds) per year. With this significant achievement, DEWA has surpassed its own previous world record of 0.94 minutes in 2024, representing an improvement of around 13%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429386479/en/ Dubai records the world’s lowest electricity customer minutes lost at just 49 seconds per year (Photo: AETOSWire) “We work in line with the vision and directives of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, to provide the best electricity and water infrastructure in the world. We utilise the latest technologies of the Fourth Industrial Revolution, particularly artificial intelligence, which we are fully i

Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance29.4.2026 15:06:00 EEST | Press release

Tecnotree, a global digital platform and services provider for AI-enabled 5G and cloud-native technologies, today announced its financial results for the first quarter of 2026, demonstrating stable revenue, strong profitability, and a robust order backlog despite geopolitical uncertainties across global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429319948/en/ Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance Key Financial Highlights – Q1 2026 Revenue of EUR 16.8 million (16.9), revenue in constant currency EUR 17.1 million, +1.0% YoY. EBIT of EUR 4.6 million (4.5), +1.8% YoY. EBIT margin of 27.4% (26.9%), +50 basis points YoY. Foreign exchange (FX) gains EUR 1.0 million (-1.4). Net income EUR 2.1 million (1.5), +36.5% YoY. Free cash flow (FCF) EUR 0.2 million (1.0). Earnings per share (EPS) EUR 0.1 (0.1). Order book at the end of the period EUR 105.4 million

SS&C Unveils WorkHQ to Power Enterprise Agentic Automation29.4.2026 15:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of SS&C Blue Prism WorkHQ, its agentic automation platform designed to help enterprises operationalize agentic AI safely, transparently and with full control of end-to-end workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429512507/en/ Unveiled at a live event at Nasdaq in New York City, WorkHQ introduces a unified control plane orchestrating people, AI agents, APIs and digital workers into a single governed environment. SS&C developed WorkHQ based on its own experience operating at scale across regulated industries. Today, SS&C supports more than 23,000 customers globally with the help of 4,000+ digital workers and more than 50 AI agents. These efforts have enabled SS&C to significantly improve operational efficiency in key processes, reducing processing times by up to 95% in key workflows. “WorkHQ was built for the enterprise problem, not

Ecolab Life Sciences Expands Global Bioprocessing Capabilities With New Advanced Development and Applications Center in Korea29.4.2026 15:00:00 EEST | Press release

Building on the continued growth and strong performance of its Life Sciences business, Ecolab is further expanding its global bioprocessing capabilities to support biopharmaceutical manufacturers worldwide. Today, Ecolab Life Sciences announced the opening of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, its first bioprocessing facility in Asia. The new center further strengthens the company’s global Life Sciences footprint and supports customers operating in one of the world’s most advanced biopharmaceutical manufacturing markets. The Korea BPAL supports a full range of process development activities from early-stage testing through studies that replicate manufacturing at scale, building on Ecolab’s established bioprocessing applications network in the United States and the United Kingdom. The facility enables hands-on collaboration with Ecolab’s bioprocessing experts to help customers optimize purification processes, enhance cost and process efficiency, and advance p

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release

Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye